CRIS

Curis

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 3

stock price surged significantly

consensus rating "Strong Buy"

EPS Below Expectations

Revenue Below Expectations

Revenue Keeps Dropping

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About CRIS

Curis, Inc.

A biotechnology company that developing innovative therapeutics for the treatment of cancer

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

08/01/2000

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.curis.com

Security Type

Common stock

Office address

128 Spring Street, Building C - Suite 500, Lexington, Massachusetts, 02421

Business

Introduction

Curis, Inc., was incorporated as a Delaware corporation in February 2000. The company is a biotechnology company focused on the development of emavusertib, an oral, small-molecule inhibitor of the interleukin -1 receptor-associated kinase.

Company Financials

EPS

CRIS has released its 2024 Q4 earnings. EPS was reported at -1.25, versus the expected -1.24, missing expectations. The chart below visualizes how CRIS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CRIS has released its 2024 Q4 earnings report, with revenue of 3.35M, reflecting a YoY change of 24.07%, and net profit of -9.62M, showing a YoY change of 17.88%. The Sankey diagram below clearly presents CRIS’s revenue sources and cost distribution.